For US residents only.

Patient Support

RYDAPT NOW—a partner during your journey

With our wide range of resources and support, the RYDAPT Care Coordinators at RYDAPT NOW can help you gain access to your medicine.
 

For both FDA-approved indications for RYDAPT, Care Coordinators are there to support you

  • Assisting you with access to RYDAPT® (midostaurin) as you transition between inpatient and outpatient settings*
  • Offering support with insurance verification to help you understand how to get your medicine and what your financial responsibilities are
    • Providing information about prior authorization requirements
    • Initiating a benefits investigation in the inpatient setting in preparation for transitioning to the outpatient setting*
  • Helping you find a pharmacy based on your insurance plan, and get your medicine according to your plan’s guidelines
  • Putting you in touch with a Clinical Educator who can provide information about your disease, side effects you may experience, and administration of RYDAPT
  • Providing information about financial assistance that may be available

*For patients with newly diagnosed FLT3+ AML only.

How to enroll in RYDAPT NOW

  • Complete the Service Request Form with your health care provider and fax it to 1-888-891-4924
    OR
  • Call 1-800-282-7630 from 9 am to 8 pm ET, Monday through Friday, to begin the enrollment process

RYDAPT NOW Care Coordinators are able to provide information in more than 160 languages.


No purchase of RYDAPT is required. Novartis cannot guarantee that every patient who enrolls in RYDAPT NOW will be successful in obtaining insurance coverage for treatment or will receive financial assistance.


Limitations apply. Call RYDAPT NOW (1-800-282-7630) for information about eligibility for the individual patient support programs.

Financial support

RYDAPT is part of the Universal Co-pay Card Program offered by Novartis Oncology

  • Commercially insured patients pay $10 per month
  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year

Limitations apply. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Offer available when RYDAPT is reimbursed by the patient's pharmacy insurance benefit. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, go to www.copay.novartisoncology.com or call 1-877-577-7756.
 

See if you're eligible

RYDAPT NOW Free Supply Programs

For appropriate patients with AML: RYDAPT NOW Access Program
 

If your doctor prescribes RYDAPT for newly diagnosed FLT3+ AML based on the approved label and there is a delay in your insurance coverage as you transition out of the hospital, you may be eligible to receive a free 14-day supply of RYDAPT shipped directly to your home to avoid disruption in your treatment.
 

For appropriate patients with any of 3 types of systemic mastocytosis (SM): RYDAPT NOW Free Trial
 

If you are prescribed RYDAPT for any of 3 types of SM, you may be eligible to receive a free 28-day supply of RYDAPT shipped directly to your home or another convenient location.
 

No purchase of RYDAPT is required. Novartis cannot guarantee that every patient who enrolls in RYDAPT NOW will be successful in obtaining insurance coverage for treatment or will receive financial assistance.
 

Clinical Educators can help you learn more about your RYDAPT treatment

Clinical Educators can help you:
 

  • Understand what to expect when taking RYDAPT throughout different stages of your treatment
  • Know what to expect when transitioning out of the hospital*

Clinical Educator interactions are limited to 2 per patient.
 

This program does not replace your regular interactions with your health care team.
 

To learn more about the program and eligibility, call RYDAPT NOW at 1-844-4RYDAPT (479-3278).
 

RYDAPT NOW is one of the ways that Novartis is committed to patient support.
 

On behalf of Novartis Patient Assistance Now Oncology and the whole team at RYDAPT NOW, we are happy to help you navigate the path along your treatment journey.
 

This program does not replace your regular interactions with your health care team.

Includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL), collectively referred to as advanced SM.

RYDAPT NOW Brought to you by Novartis Patient Assistance Now Oncology RYDAPT NOW Brought to you by Novartis Patient Assistance Now Oncology RYDAPT NOW Brought to you by Novartis Patient Assistance Now Oncology